The purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications for investigator-initiated exploratory clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). The trials must address questions within the mission and research interests of the NINDS and may evaluate drugs, biologics, and devices, as well as surgical, behavioral and rehabilitation therapies. Information about the mission and research interests of the NINDS can be found at the NINDS website (http://www.ninds.nih.gov/)
The purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications for investigator-initiated efficacy clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). The trials must address questions within the mission and research interests of the NINDS and may evaluate drugs, biologics, and devices, as well as surgical, behavioral and rehabilitation therapies. Information about the mission and research interests of the NINDS can be found at the NINDS website (http://www.ninds.nih.gov/)
This Funding Opportunity Announcement (FOA) invites research grant applications focused on defining and understanding the pathogenic mechanisms involved in Human Immunodeficiency Virus (HIV)-1 induced CNS dysfunction, but within the context of viral suppression and Antiretroviral therapy (ART). The FOA further supports research to identify therapeutic targets against which treatments may be developed to prevent the neurobehavioral and neurological co-morbidities in HIV-1 infected individuals. Basic and translational research in domestic and international settings are of interest. Multidisciplinary research teams and collaborative alliances are encouraged but not required.
The Office of Research on Womens Health (ORWH) announces the availability of administrative supplements to support research highlighting the impact of sex/gender influences at the intersection of race/ethnicity and other social determinants in human health and illness, including preclinical, clinical and behavioral studies. The purpose of this FOA is to provide Administrative Supplements to active NIH parent grants for one year to address health disparities among women of populations in the US who are underrepresented, understudied and/or underreported in biomedical research.
The Jointly Sponsored NIH Predoctoral Training Program in the Neurosciences (JSPTPN) is an institutional program that supports broad and fundamental research training in the neurosciences. In addition to a broad education in the neurosciences, a key component will be a curriculum that provides a strong foundation in experimental design, statistical methodology and quantitative reasoning. . JSPTPN programs are intended to be two years in duration, and students may only be appointed to this training grant during the first 2 years of their graduate research training. The primary objective is to prepare individuals for careers in neuroscience that will have a significant impact on our understanding of nervous system function and the health-related research needs of the nation.
The Office of Research on Women's Health (ORWH) announces the availability of administrative supplements to support research highlighting the impact of sex/gender influences and/or sex and gender factors in human health and illness, including basic, preclinical, clinical and behavioral studies. Of special interest are studies relevant to understanding the significance of biological sex on cells and tissue explants; comparative studies of male and female tissues, organ systems and physiological systems; sex-based comparisons of pathophysiology, biomarkers, gene expression, clinical presentation and prevention and treatment of diseases. The most robust experimental designs include consideration of both sex and gender; therefore, applications proposing to investigate the influence of both sex and gender factors are highly encouraged. The proposed research must address at least one objective from Goals 1 through 3 of the NIH Strategic Plan for Women's Health Research.
The purpose of this FOA is to solicit UG3/UH3 phased cooperative agreement research applications to conduct efficient, large-scale pragmatic clinical trial Demonstration Projects within the NIH-DoD-VA Pain Management Collaboratory on non-pharmacological approaches to pain management and other co-morbid conditions in U.S. military personnel, veterans and their families. This program will be referred to as the NIH-DoD-VA Pain Management Collaboratory program. Awards made under this FOA will initially support a two-year milestone-driven planning phase (UG3), with possible transition to a pragmatic trial Demonstration Project implementation phase (UH3). UG3 projects that have met the scientific milestone and feasibility requirements may transition to the UH3 phase. The UG3/UH3 application must be submitted as a single application, following the instructions described in this FOA. The overall goal of this initiative, jointly supported by the NIH, DoD, and VA, is to develop the capacity to implement cost-effective large-scale clinical research in military and veteran health care delivery organizations focusing on non-pharmacological approaches to pain management and other comorbid conditions. The NIH, DoD, and VA expect to: establish a Coordinating Center that will provide national leadership and technical expertise for all aspects of health care system (HCS_- focused research including assistance to UG3/UH3 grant applicants. Primary outcomes of treatment interventions include assessing pain and pain reduction, ability to function in daily life, quality of life, and medication usage/reduction/discontinuation. Secondary outcomes focusing on assessing comorbid conditions or those co-occurring with high frequency in this population are also of interest under the FOA.
The purpose of this FOA is to support the genetic discovery, replication and validation of disease causing mutations, risk variants and genetic modifiers which contribute to the pathophysiology, proteinopathies and clinical heterogeneity representative of the neurological syndromes that are classified under the broad spectrum of Frontotemporal Degeneration (FTD). The FTD Sequencing Consortium FOA will support whole genome sequencing, replication and functional variant validation studies of FTD case/control and family-based cohorts identified through clinical diagnosis or autopsy confirmation.
This FOA solicits applications for exploratory research projects that use innovative, methodologically-integrated approaches to understand how circuit activity gives rise to mental experience and behavior. Applications should offer a limited scope of aims and an approach that will establish feasibility, validity or other technically qualifying results that, if successful, would support a potential, subsequent Targeted Brain Circuits Projects - TargetedBCP R01, as described in the companion FOA (RFA-NS-17-014).
This FOA solicits applications for research projects that use innovative, methodologically-integrated approaches to understand how circuit activity gives rise to mental experience and behavior. The goal is to support projects that can realize a meaningful outcome within 5 years. Applications should address circuit function in the context of specific neural systems such as sensation, perception, attention, reasoning, intention, decision-making, emotion, navigation, communication or homeostasis. Projects should link theory and data analysis to experimental design and should produce predictive models as deliverables. Projects should aim to improve the understanding of circuits of the central nervous system by systematically controlling stimuli and/or behavior while actively recording and/or manipulating dynamic patterns of neural activity. Projects can use non-human animal species, and applications should explain how the selected species offers ideal conditions for revealing general principles about the circuit basis of a specific behavior.